靶向B细胞与小胶质细胞的布鲁顿酪氨酸激酶抑制剂治疗多发性硬化:综述
本综述指出B细胞在多发性硬化(MS)中具致病作用,靶向布鲁顿酪氨酸激酶(BTK)可同时抑制B细胞受体介导的B细胞活化及巨噬细胞、小胶质细胞等髓系细胞活化;不同在研化合物的结合模式、选择性、相对抑制浓度及入中枢神经系统能力各异,复发缓解型与进展型MS的临床试验已获鼓舞人心的疗效与安全性数据,但长期效应、抗体水平变化及治疗定位等问题尚待解答。
要点
- BTK参与B细胞受体介导的B细胞活化及巨噬细胞、小胶质细胞等髓系细胞活化。
- 不同BTK抑制剂在结合模式、选择性、相对抑制浓度及入中枢神经系统能力上存在差异。
- 复发缓解型与进展型MS的BTK抑制剂临床试验已获鼓舞人心的疗效与安全性数据。
核心结论
- 靶向BTK是极具前景的新策略,但BTK抑制剂治疗炎症性中枢神经系统疾病的长期效应等问题尚未解答。
- 应评估循环抗体水平的潜在变化并与B细胞清除进行比较。
- BTK抑制剂能否进入中枢神经系统取决于具体化合物。
- BTK抑制剂在MS治疗格局中的定位尚待明确。
- 需对BTK抑制剂的不同特性进行比较分析,以确定哪些抑制剂可用于复发型与进展型MS,并明确哪种药物最适合在抗CD20治疗后序贯使用。
研究设计与样本
- 本文为综述,围绕靶向B细胞与小胶质细胞的BTK抑制剂在多发性硬化中的机制、在研化合物特点及临床试验数据展开论述。
主要发现
- 现有MS疾病修饰治疗采用4种作用机制:免疫调节、抑制免疫细胞增殖、抑制免疫细胞迁移或细胞清除。
- B细胞清除抗体针对表面分子CD20的经验性成功,推动了B细胞在多发性硬化中致病作用的认识。
- B细胞持续缺失可能带来安全性风险,如内源性免疫球蛋白产生下降。
- BTK抑制剂可同时作用于B细胞受体介导的B细胞活化及髓系细胞活化。
- 复发缓解型MS与进展型MS患者中正在开展BTK抑制剂临床试验,迄今疗效与安全性数据令人鼓舞。
临床怎么用
- 原文未据此给出推荐。
局限性
- BTK抑制剂治疗炎症性中枢神经系统疾病的长期效应尚不清楚。
- 循环抗体水平的潜在变化应被评估并与B细胞清除进行比较。
- BTK抑制剂进入中枢神经系统的能力取决于具体化合物。
- BTK抑制剂在多发性硬化治疗格局中的定位尚待明确。
- 需进行比较分析以确定哪些抑制剂可用于复发型与进展型多发性硬化,并明确抗CD20治疗后最合适的序贯药物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Currently, disease-modifying therapies for multiple sclerosis (MS) use 4 mechanisms of action: immune modulation, suppressing immune cell proliferation, inhibiting immune cell migration, or cellular depletion. Over the last decades, the repertoire substantially increased because of the conceptual progress that not only T cells but also B cells play an important pathogenic role in MS, fostered by the empirical success of B cell-depleting antibodies against the surface molecule CD20. Notwithstanding this advance, a continuous absence of B cells may harbor safety risks, such as a decline in the endogenous production of immunoglobulins. Accordingly, novel B cell-directed MS therapies are in development, such as inhibitors targeting Bruton tyrosine kinase (BTK). OBSERVATIONS: BTK is centrally involved in the B cell receptor-mediated activation of B cells, one key requirement in the development of autoreactive B cells, but also in the activation of myeloid cells, such as macrophages and microglia. Various compounds in development differ in their binding mode, selectivity and specificity, relative inhibitory concentration, and potential to enter the central nervous system. The latter may be important in assessing whether BTK inhibition is a promising strategy to control inflammatory circuits within the brain, the key process that is assumed to drive MS progression. Accordingly, clinical trials using BTK inhibitors are currently conducted in patients with relapsing-remitting MS as well as progressive MS, so far generating encouraging data regarding efficacy and safety. CONCLUSIONS AND RELEVANCE: While the novel approach of targeting BTK is highly promising, several questions remain unanswered, such as the long-term effects of using BTK inhibitors in the treatment of inflammatory CNS disease. Potential changes in circulating antibody levels should be evaluated and compared with B cell depletion. Also important is the potential of BTK inhibitors to enter the CNS, which depends on the given compound. Remaining questions involve where BTK inhibitors fit in the landscape of MS therapeutics. A comparative analysis of their distinct properties is necessary to identify which inhibitors may be used in relapsing vs progressive forms of MS as well as to clarify which agent may be most suitable for sequential use after anti-CD20 treatment.
引用
- Dybowski S, Torke S, Weber MS, et al. Targeting B Cells and Microglia in Multiple Sclerosis With Bruton Tyrosine Kinase Inhibitors: A Review. JAMA Neurol. 2023. PMID: 36780171. doi:10.1001/jamaneurol.2022.5332
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。